Xenon Pharmaceuticals’ (XENE) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright restated their buy rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $53.00 price target on the biopharmaceutical company’s stock. Other research analysts have also issued reports about the company. Needham & Company LLC reiterated a “buy” […]
HC Wainwright restated their buy rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $53.00 price target on the biopharmaceutical company’s stock. Other research analysts have also issued reports about the company. Needham & Company LLC reiterated a “buy” […]
